Trials / Conditions / Squamous Cell Carcinoma of the Oral Cavity

Squamous Cell Carcinoma of the Oral Cavity

24 registered clinical trials studyying Squamous Cell Carcinoma of the Oral Cavity — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Antitumor-B KAC PK Study NCT05452408	Medical College of Wisconsin	Phase 1
Withdrawn	Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC NCT05608369	Case Comprehensive Cancer Center	Phase 2
Recruiting	Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Out NCT06380686	AIO-Studien-gGmbH	—
Not Yet Recruiting	CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC NCT06609070	Guangzhou University of Traditional Chinese Medicine	N/A
Recruiting	De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck NCT06030440	University of Erlangen-Nürnberg Medical School	Phase 2 / Phase 3
Active Not Recruiting	Contribution of Residual Tumour DNA Testing on the Surgical Bed NCT05934929	Centre Henri Becquerel	N/A
Active Not Recruiting	Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had S NCT05540899	American College of Radiology	Phase 1
Recruiting	Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer NCT04191460	Erasmus Medical Center	Phase 2
Withdrawn	Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) NCT04831450	University of Miami	Phase 2
Completed	Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer NCT03459729	Medical College of Wisconsin	EARLY_Phase 1
Completed	CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer NCT03721757	The Clatterbridge Cancer Centre NHS Foundation Trust	Phase 2
Completed	Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study NCT03575598	University Health Network, Toronto	EARLY_Phase 1
Completed	Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma NCT03370276	H. Lee Moffitt Cancer Center and Research Institute	Phase 1 / Phase 2
Unknown	Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcino NCT03364166	Cairo University	N/A
Completed	Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell NCT02873819	Gliknik Inc.	Phase 2
Unknown	Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients NCT04387682	National Taiwan University Hospital	N/A
Completed	IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavit NCT02609386	Brooklyn ImmunoTherapeutics, LLC	Phase 2
Terminated	Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity NCT02331875	Innate Pharma	Phase 1 / Phase 2
Completed	A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the H NCT01921426	Galera Therapeutics, Inc.	Phase 1
Completed	Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity NCT01636544	Institut Pasteur	N/A
Completed	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity NCT01265849	CEL-SCI Corporation	Phase 3
Terminated	A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Muc NCT01077869	University Hospital, Ghent	—
Completed	TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer NCT01108042	Orlando Guntinas-Lichius, Prof. Dr. med.	Phase 1 / Phase 2
Completed	Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium NCT01321892	Icahn School of Medicine at Mount Sinai	—